Pacira Biosciences, Inc. (NASDAQ:PCRX)

About the company

Pacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.

Sector

Health Technology

Industry

Pharmaceuticals: Other

Employees

606

CEO

David M. Stack

Exchange

NASDAQ

Website

http://www.pacira.com

$435.00M

Total Revenue

606

Employees

$2B

Market Capitalization

-5654.00

Price/Earning ratio

Stock price

Gross Margin (in %)

Total gross margin

$326M

Operating Margin (in %)

Total operating margin

$47M

Net Margin (in %)

Total net margin

$0M

Dividend Yield (in %)

Dividend per share

$0

Industry peers

Name Ticker Market capitalization (in USD Million) Revenues (in USD Million) Price/Book Price/Earning Net margin (in %)
Horizon Therapeutics Plc HZNP 12030.90 1376.00 5.13 18.97 43.06
Catalent, Inc. CTLT 10896.37 2872.00 5.47 104.47 3.63
Perrigo Co. Plc PRGO 7525.41 4837.00 1.29 51.34 3.02
Bausch Health Cos., Inc. BHC 6195.15 8597.00 8.65 -3.27 -21.96
Jazz Pharmaceuticals Plc JAZZ 6129.78 2188.00 2.12 22.40 12.81
United Therapeutics Corp. UTHR 5064.54 1443.00 1.76 9.77 36.59
MyoKardia, Inc. MYOK 4325.84 34.00 12.57 -13.95 -201.73
Axsome Therapeutics, Inc. AXSM 3004.40 None 20.39 -33.40 None
Pacira Biosciences, Inc. PCRX 2374.68 435.00 6.37 -5654.00 -0.02
ArQule, Inc. ARQL 2240.00 5.00 15.75 -55.56 -808.06
SAGE Therapeutics, Inc. SAGE 2181.92 9.00 2.56 -3.37 -413.06
Corcept Therapeutics, Inc. CORT 2054.48 335.00 4.72 19.36 31.64
Prestige Consumer Healthcare, Inc. PBH 1862.52 963.00 1.57 13.14 14.77
Madrigal Pharmaceuticals, Inc. MDGL 1617.30 0.00 4.32 -15.83 -624.74
Ironwood Pharmaceuticals, Inc. IRWD 1595.90 440.00 -22.59 18.82 19.14
Revolution Medicines, Inc. RVMD 1567.34 48.00 4.07 -22.14 -146.29
Innoviva, Inc. INVA 1539.06 285.00 3.64 7.96 66.41
Intercept Pharmaceuticals, Inc. ICPT 1409.60 272.00 -41.95 -4.11 -127.53
Portola Pharmaceuticals, Inc. PTLA 1329.78 121.00 19.53 -4.77 -232.73
Supernus Pharmaceuticals, Inc. SUPN 1274.94 402.00 2.02 10.93 28.90
Zogenix, Inc. ZGNX 1272.60 5.00 3.47 -2.99 -241.62
Revance Therapeutics, Inc. RVNC 1230.46 0.00 4.86 -6.59 41.82
Theravance Biopharma, Inc. TBPH 1136.58 88.00 -7.98 -4.61 -280.80
Amphastar Pharmaceuticals, Inc. AMPH 1053.50 327.00 2.63 20.67 15.90
Endo International Plc ENDP 777.48 3014.00 -1.06 -2.77 -9.09
BellRing Brands, Inc. BRBR 771.22 954.00 -0.42 5.85 13.98
Assembly Biosciences, Inc. ASMB 693.39 16.00 3.11 -6.97 -601.75
Eagle Pharmaceuticals, Inc. EGRX 648.90 192.00 3.49 257.50 1.29
Aerie Pharmaceuticals, Inc. AERI 616.86 79.00 4.89 -3.05 -252.92
Collegium Pharmaceutical, Inc. COLL 581.06 299.00 4.16 -44.97 -4.21
Catalyst Pharmaceuticals, Inc. CPRX 543.56 119.00 5.29 12.39 36.09
Anika Therapeutics, Inc. ANIK 494.20 125.00 1.71 17.83 22.73
Intersect ENT, Inc. XENT 445.76 102.00 4.21 -8.93 -48.61
BioDelivery Sciences International, Inc. BDSI 392.84 130.00 5.62 -53.37 -5.01
ANI Pharmaceuticals, Inc. ANIP 367.56 203.00 1.88 -235.62 -0.67
Albireo Pharma, Inc. ALBO 331.24 11.00 3.37 -4.33 -730.55
MEI Pharma, Inc. MEIP 284.69 5.00 4.90 -7.30 -539.48
Mallinckrodt Plc MNK 199.08 3037.00 0.11 -0.17 -39.56
Agile Therapeutics, Inc. AGRX 161.66 None 2.63 -7.83 None
Marinus Pharmaceuticals, Inc. MRNS 161.60 0.00 6.26 -2.40 None
Cerecor, Inc. CERC 119.60 7.00 7.65 -5.31 -429.22
Ampio Pharmaceuticals, Inc. AMPE 95.81 1.00 67.00 -5.15 None
Evoke Pharma, Inc. EVOK 86.88 None 30.17 -12.93 None
AcelRx Pharmaceuticals, Inc. ACRX 85.60 2.00 -1.57 -1.53 -644.25
CTI BioPharma Corp. CTIC 83.78 3.00 3.74 -2.03 -111.83
Zynerba Pharmaceuticals, Inc. ZYNE 78.66 0.00 1.29 -2.19 -699.94
Adamas Pharmaceuticals, Inc. ADMS 71.96 57.00 -4.59 -0.78 -160.44
Aclaris Therapeutics, Inc. ACRS 68.88 4.00 1.21 -0.50 None
Oramed Pharmaceuticals, Inc. ORMP 60.48 3.00 4.87 -4.73 -464.15
Cassava Sciences, Inc. SAVA 59.28 41.00 3.12 -13.00 76.71
Cumberland Pharmaceuticals, Inc. CPIX 49.20 47.00 1.00 -10.93 -9.59
SCYNEXIS, Inc. SCYX 48.95 0.00 10.28 -1.26 -30.84
Natural Alternatives International, Inc. NAII 46.55 114.00 0.64 -12.31 -3.19
IsoRay, Inc. ISR 42.88 9.00 8.00 -12.80 -36.08
Lipocine, Inc. LPCN 39.60 0.00 9.43 -2.64 None
Acasti Pharma, Inc. ACST 35.84 827.00 2.33 -0.58 -7.45
Neos Therapeutics, Inc. NEOS 34.50 65.00 -2.65 -1.97 -26.74
PLx Pharma, Inc. PLXP 27.00 0.00 -2.59 -2.86 119.04
CytRx Corp. CYTR 22.11 0.00 1.60 -3.19 408.46
EyeGate Pharmaceuticals, Inc. EYEG 20.80 3.00 2.59 -1.76 -264.21
Regulus Therapeutics, Inc. RGLS 17.64 0.00 1.56 -0.82 -272.13
Tetraphase Pharmaceuticals, Inc. TTPH 12.65 8.00 0.67 -0.15 -798.18
Intec Pharma Ltd. NTEC 10.66 None 1.37 -0.25 None
Hepion Pharmaceuticals, Inc. HEPA 7.38 None 2.31 -0.62 None
VIVUS, Inc. VVUS 6.88 73.00 -0.15 -0.23 -39.28
Sonoma Pharmaceuticals, Inc. SNOA 6.37 19.00 1.01 -2.04 -25.58
KemPharm, Inc. KMPH 6.02 15.00 -0.17 -0.35 -120.48
Tonix Pharmaceuticals Holding Corp. TNXP 4.27 None 1.07 -0.09 None
Ritter Pharmaceuticals, Inc. RTTR 0.45 None 0.17 -0.03 None

Latest insider transactions

Date Role Name Transaction Quantity Quantity Owned After

Pacira BioSciences, Inc. Announces Pricing of $350.0 Million Aggregate Principal Amount of 0.750% Convertible Senior Notes due 2025

1d ago, source: YAHOO!

Pacira BioSciences, Inc. (PCRX) today announced the pricing of $350.0 million aggregate principal amount of convertible senior notes due 2025 (the “notes”) in a private placement to qualified ...

Pacira BioSciences, Inc. Announces Proposed Offering of $300.0 Million Aggregate Principal Amount of Convertible Senior Notes

2d ago, source: Benzinga.com

Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it intends to offer, subject to market and other conditions, ...

Pacira (PCRX) Provides Preliminary Results for Second Quarter

1d ago, source: YAHOO!

Pacira (PCRX) reports preliminary results for the second quarter of 2020. The company's product sales are hurt by the COVID-19 pandemic. The stock fell in pre-market trading.

FY2021 EPS Estimates for Pacira Biosciences Inc (NASDAQ:PCRX) Lifted by SVB Leerink

5d ago, source: modernreaders.com

Research analysts at SVB Leerink upped their FY2021 earnings per share estimates for Pacira Biosciences in a report released ...

Pacira BioSciences Announces Conclusion of EXPAREL Agreement with DePuy Synthes

7d ago, source: Stockhouse

PARSIPPANY, N.J., July 02, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative non-opioid pain management options, today announced that the company has ...

Will Pacira BioSciences Continue to Surge Higher?

6d ago, source: Nasdaq

As of late, it has definitely been a great time to be an investor of Pacira BioSciences, Inc. PCRX. The stock has moved higher by 15.2% in the past month, while it is also above its 20 Day SMA too.

BRIEF-Pacira Biosciences Announces Pricing Of $350 Mln Aggregate Principal Amount Of 0.750% Convertible Senior Notes Due 2025

14h ago, source: Reuters

PACIRA BIOSCIENCES, INC. ANNOUNCES PRICING OF $350.0 MILLION AGGREGATE PRINCIPAL AMOUNT OF 0.750% CONVERTIBLE SENIOR NOTES DUE 2025 Source text for Eikon: Further company coverage: Our Standards:The ...



Portfolio items

Follow companies to create your optimal portfolio.
or
Refresh this page to see your newly added stocks.